123 related articles for article (PubMed ID: 16432449)
21. MEK Inhibition Enhances Preclinical Activity of BRAF Inhibition and Immunotherapy.
Cancer Discov; 2015 May; 5(5):OF12. PubMed ID: 25813351
[No Abstract] [Full Text] [Related]
22. Reactive oxygen species may have antitumor activity in metastatic melanoma.
Tuma RS
J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
[No Abstract] [Full Text] [Related]
23. Drug targeting of oncogenic pathways in melanoma.
Fecher LA; Amaravadi RK; Schuchter LM; Flaherty KT
Hematol Oncol Clin North Am; 2009 Jun; 23(3):599-618, x. PubMed ID: 19464605
[TBL] [Abstract][Full Text] [Related]
24. Advances in the treatment of late stage melanoma.
Walkington LA; Lorigan P; Danson SJ
BMJ; 2013 Mar; 346():f1265. PubMed ID: 23460638
[No Abstract] [Full Text] [Related]
25. Protein phosphorylation goes negative.
Pawson T; Taylor L
Mol Cell; 2009 Apr; 34(2):139-40. PubMed ID: 19394291
[TBL] [Abstract][Full Text] [Related]
26. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
27. [Signal transduction in melanoma].
Yokoyama S
Seikagaku; 2013 Jun; 85(6):469-74. PubMed ID: 23875475
[No Abstract] [Full Text] [Related]
28. Targeting x-linked inhibitor of apoptosis protein for melanoma therapy: the need for more homogeneous samples and the importance of cell lines.
Kwatra SG
J Invest Dermatol; 2011 Mar; 131(3):797. PubMed ID: 21068753
[No Abstract] [Full Text] [Related]
29. B-Raf kinase inhibitors for cancer treatment.
Li N; Batt D; Warmuth M
Curr Opin Investig Drugs; 2007 Jun; 8(6):452-6. PubMed ID: 17621874
[TBL] [Abstract][Full Text] [Related]
30. Molecular classification of patients with malignant melanoma for new therapeutic strategies.
Palmieri G; Casula M; Ascierto PA; Tanda F; Cossu A
J Clin Oncol; 2007 Jun; 25(16):e20-1. PubMed ID: 17538155
[No Abstract] [Full Text] [Related]
31. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
32. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
[TBL] [Abstract][Full Text] [Related]
33. Transforming growth factor-beta in cutaneous melanoma.
Javelaud D; Alexaki VI; Mauviel A
Pigment Cell Melanoma Res; 2008 Apr; 21(2):123-32. PubMed ID: 18426405
[TBL] [Abstract][Full Text] [Related]
34. Dichloromethane fraction of Cimicifuga heracleifolia decreases the level of melanin synthesis by activating the ERK or AKT signaling pathway in B16F10 cells.
Jang JY; Lee JH; Kang BW; Chung KT; Choi YH; Choi BT
Exp Dermatol; 2009 Mar; 18(3):232-7. PubMed ID: 18803655
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacologic therapy of melanoma of the skin].
Dement'eva NP; Koroleva LA
Sov Med; 1987; (2):49-53. PubMed ID: 3576316
[No Abstract] [Full Text] [Related]
36. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
37. MITF pathway mutations in melanoma.
Yokoyama S; Salma N; Fisher DE
Pigment Cell Melanoma Res; 2009 Aug; 22(4):376-7. PubMed ID: 19558635
[No Abstract] [Full Text] [Related]
38. Constitutive activation of the phosphatidyl inositol 3 kinase signalling pathway in acral lentiginous melanoma.
Muchemwa FC; Ma D; Inoue Y; Curtin JA; Bastian BC; Ihn H; Kageshita T
Br J Dermatol; 2008 Feb; 158(2):411-3. PubMed ID: 17999703
[No Abstract] [Full Text] [Related]
39. Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma.
Hersey P
Curr Opin Oncol; 2006 Mar; 18(2):189-96. PubMed ID: 16462190
[TBL] [Abstract][Full Text] [Related]
40. Squamoproliferative skin lesion during braf inhibitors:one size does not fit all.
Mandalà M; Gianatti A; Massi D
J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):389-91. PubMed ID: 23763655
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
